Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4050022 | 0.91 | GAA (0.44) | PDE4BTACR3PDE4APDE4CPDE4D | |
| SCHEMBL4049916 | 0.89 | PDE4B (0.43) | PDE4BSMN1; SMN2TACR3PDE4APDE4C | |
| SCHEMBL4049469 | 0.88 | PDE4B (0.48) | PDE4BSMN1; SMN2PDE4APDE4CPDE4D | |
| SCHEMBL4048502 | 0.88 | PDE4B (0.45) | PDE4BSMN1; SMN2PDE4APDE4CPDE4D | |
| SCHEMBL4055629 | 0.88 | PDE4B (0.44) | PDE4BLMNAHTTTP53RECQL | |
| SCHEMBL4051437 | 0.88 | PDE4B (0.42) | PDE4BSMN1; SMN2LMNAHTTGAA | |
| SCHEMBL4055308 | 0.87 | PDE4B (0.47) | PDE4BSMN1; SMN2PDE4APDE4CPDE4D | |
| SCHEMBL4053623 | 0.87 | PDE4B (0.45) | PDE4BSMN1; SMN2TACR3PDE4APDE4C | |
| SCHEMBL4052853 | 0.87 | SMN1; SMN2 (0.42) | PDE4BSMN1; SMN2LMNAHTTTP53 | |
| SCHEMBL4052589 | 0.86 | PDE4B (0.43) | PDE4BSMN1; SMN2PDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029996-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-01-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029996-A1 | phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease | PDE12, PDE4A, PDE4B | PDE4B 3/4885SMN1; SMN2 4776/4885TACR3 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.